Healthcare -
Biotechnology - NASDAQ - US
$ 2.52
1.2 %
$ 73 M
Market Cap
-1.03
P/E
1. INTRINSIC VALUE
Balance Sheet
Aerovate Therapeutics, Inc.
| Current Assets | 80.1 M |
| Cash & Short-Term Investments | 78.6 M |
| Receivables | 0 |
| Other Current Assets | 1.49 M |
| Non-Current Assets | 215 K |
| Long-Term Investments | 0 |
| PP&E | 215 K |
| Other Non-Current Assets | 0 |
| Current Liabilities | 3.83 M |
| Accounts Payable | 224 K |
| Short-Term Debt | 417 K |
| Other Current Liabilities | 3.19 M |
| Non-Current Liabilities | 70 K |
| Long-Term Debt | 0 |
| Other Non-Current Liabilities | 70 K |
EFFICIENCY
Earnings Waterfall
Aerovate Therapeutics, Inc.
| Revenue | 0 |
| Cost Of Revenue | 0 |
| Gross Profit | 0 |
| Operating Expenses | 74.6 M |
| Operating Income | -74.6 M |
| Other Expenses | -4.97 M |
| Net Income | -69.6 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Aerovate Therapeutics, Inc.
| Net Income | -69.6 M |
| Depreciation & Amortization | 282 K |
| Capital Expenditures | 0 |
| Stock-Based Compensation | 11.3 M |
| Change in Working Capital | -9 M |
| Others | -13.2 M |
| Free Cash Flow | -71.2 M |
Wall Street Analysts Price Targets
Aerovate Therapeutics, Inc.
Wall Street analysts predict an average 1-year price target for AVTE of $18 , with forecasts ranging from
a
low of
$2 to a high of $65 .
AVTE Lowest Price Target
Wall Street Target
2 USD
-20.63%
AVTE Average Price Target
Wall Street Target
18 USD
614.29%
AVTE Highest Price Target
Wall Street Target
65 USD
2479.37%
4. DIVIDEND
ANALYSIS
AVTE does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Aerovate Therapeutics, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
1.85 M USD 5
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
1.55 M USD 1
9-12 MONTHS
7. News
Aerovate Therapeutics Announces Range of Expected Cash Dividend in Connection with the Proposed Merger with Jade Biosciences
Cash dividend expected to be in the range of $67.6 – 69.6 million WALTHAM, Mass. , April 7, 2025 /PRNewswire/ -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE) ("Aerovate") today announced that, in connection with its previously announced merger (the "Merger") with Jade Biosciences, Inc. ("Jade"), it expects to declare a cash dividend to the pre-Merger Aerovate stockholders (the "Cash Dividend") in the range of $67.6 – 69.6 million in the aggregate.
prnewswire.com
- 1 week ago
AEROVATE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Aerovate Therapeutics, Inc. - AVTE
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Aerovate Therapeutics, Inc. (NasdaqGM: AVTE) and Jade Biosciences. Pursuant to the terms of the agreement, shareholders of Aerovate will own approximately 1.6% of the combined company. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the m.
businesswire.com
- 3 weeks ago
AVTE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Aerovate Therapeutics, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Aerovate Therapeutics, Inc. (NASDAQ: AVTE) and Jade Biosciences is fair to Aerovate shareholders. Upon closing of the proposed transaction, Aerovate stockholders are expected to own approximately 1.6% of the combined company. Halper Sadeh encourages Aerovate shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212.
businesswire.com
- 3 months ago
INVESTOR ALERT: The M&A Class Action Firm Investigates the Merger of Aerovate Therapeutics, Inc. – AVTE
NEW YORK, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Aerovate Therapeutics, Inc. (Nasdaq: AVTE ), relating to a proposed merger with Jade Biosciences. Under the terms of the agreement, pre-merger Aerovate stockholders are expected to own approximately 1.6% of the combined company, while pre-merger Jade stockholders are expected to own approximately 98.4% of the combined entity.
globenewswire.com
- 5 months ago
INVESTOR ALERT: The M&A Class Action Firm Investigates the Merger of Aerovate Therapeutics, Inc. - AVTE
NEW YORK , Nov. 3, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Aerovate Therapeutics, Inc. (Nasdaq: AVTE ), relating to a proposed merger with Jade Biosciences.
prnewswire.com
- 5 months ago
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AVTE and PFIE on Behalf of Shareholders
NEW YORK , Nov. 1, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Aerovate Therapeutics, Inc. (NASDAQ: AVTE)'s merger with Jade Biosciences. Upon closing of the proposed transaction, Aerovate stockholders are expected to own approximately 1.6% of the combined company.
prnewswire.com
- 5 months ago
AVTE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Aerovate Therapeutics, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Aerovate Therapeutics, Inc. (NASDAQ: AVTE) and Jade Biosciences is fair to Aerovate shareholders. Upon closing of the proposed transaction, Aerovate stockholders are expected to own approximately 1.6% of the combined company. Halper Sadeh encourages Aerovate shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212.
businesswire.com
- 5 months ago
Shareholder Alert: Ademi LLP Investigates Whether Aerovate Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders
MILWAUKEE--(BUSINESS WIRE)--Ademi LLP is investigating Aerovate (Nasdaq: AVTE) for possible breaches of fiduciary duty and other violations of law in its transaction with Jade. Click here to learn how to join our investigation or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you. Under the agreement, Aerovate stockholders are expected to own approximately 1.6% of the combined company, while Jade stockholders — including those investors participating in the pre-clo.
businesswire.com
- 5 months ago
Aerovate Therapeutics to Explore Strategic Alternatives
WALTHAM, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), which previously announced it was halting enrollment and shutting down the Phase 3 portion of the Inhaled iMatinib Pulmonary Arterial Hypertension Clinical Trial (IMPAHCT) as well as the long-term extension study, today announced that it will conduct a comprehensive review of strategic alternatives focused on maximizing shareholder value.
globenewswire.com
- 9 months ago
The 3 Hottest Stock Downgrades From Last Week
Wall Street's leading analysts have been adjusting their S&P 500 forecasts in recent days. Driven by potential Federal Reserve interest rate cuts, strong performance from large technology companies and solid corporate earnings growth, analysts expect the S&P 500 to consolidate its gains above 5500.
investorplace.com
- 9 months ago
Investigation Into Aerovate Therapeutics, Inc. (AVTE) Announced byHolzer & Holzer, LLC
ATLANTA, June 21, 2024 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Aerovate Therapeutics, Inc. (“Aerovate” or the “Company”) (NASDAQ: AVTE) complied with federal securities laws. On June 17, 2024, Aerovate announced topline results from the Phase 2b portion of the Phase 2b/Phase 3 Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial and stated that “the study did not meet its primary endpoint for improvement in pulmonary arterial hypertension (“PVR”) compared to placebo for any of the studied doses or show meaningful improvements in the secondary endpoint of change in six minute walk distance.” Following this news, the price of the Company's stock dropped.
globenewswire.com
- 9 months ago
Aerovate Therapeutics Investors: Investigation on behalf of investors; the Portnoy Law Firm
Investors can contact the law firm at no cost to learn more about recovering their losses
globenewswire.com
- 9 months ago
8. Profile
Summary
Aerovate Therapeutics, Inc. AVTE
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 73 M
Dividend Yield
0.00%
Description
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Contact
930 Winter Street, Waltham, MA, 02116
https://aerovatetx.com
IPO
Date
June 30, 2021
Employees
30
Officers
Mr. Timothy P. Noyes M.B.A.
Chief Executive Officer & Director
Mr. Hunter Gillies M.D.
Chief Medical Officer
Dr. Benjamin T. Dake Ph.D.
Founder, President, Chief Operating Officer & Secretary
Mr. George A. Eldridge
Chief Financial Officer & Treasurer
Ms. Susan Fischer
Executive Vice President of Development Operations
Ms. Donna Dea
Head of Regulatory Affairs
Dr. Cheryl Lassen BSc., M.D., MBBCh
Senior Vice President of Clinical Development
Dr. Ralph W. Niven M.B.A., M.R, Ph.D., Pharm.S
Chief Scientific Officer
Mr. Stephen K. Yu
Senior Vice President of Quality
Dr. Sanjeev Khindri
Executive Vice President of Clinical Development